Transaction · 0001628280-26-060491

Hollander David

Hollander David, CR, DO, reported a transaction classified as grant at Veradermics, Inc involving 19300.000000 shares for an estimated $0.00. Reported holdings after the transaction were 19300.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACR, DO
MANEVeradermics, Inc
Filing timeSep 03
Trade dateSep 01, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$97.75
Pre-filing
1mo ago +7.4%1w ago +5.0%1d ago +0.7%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

MANE price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
MANE since 2026-09-03Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001628280-26-060491
Stock Option (Right to Buy)
Transaction date
Sep 01, 2026
Filed Sep 03, 2026, 08:35 PM · 2d delay
Shares
19.3k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
19.3k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership Large Holdings Increase
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief R&D Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These shares represent restricted stock units (RSUs) granted under the Veradermics, Incorporated 2026 Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock. The R…

  2. F2

    The option vests as to 25% of the underlying shares of Common Stock on September 1, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly insta…

Original filing · 0001628280-26-060491
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

MANE